StreetInsider.com News Articles

Genesco Inc. to Present at 2026 ICR Conference on January 12, 2026

Tue, 23 Dec 2025 06:50:00 -0500

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Genesco Inc. (NYSE: GCO) today announced that its management team will present at the 2026 ICR Conference on Monday, January 12, 2026. A webcast of the presentation is scheduled to begin at 9:30 a.m. (Eastern time) and may be accessed through Genesco’s investor relations page at www.genesco.com.

About Genesco Inc.

Genesco Inc. (NYSE: GCO) is a footwear focused company with distinctively positioned retail and lifestyle brands and proven omnichannel capabilities offering customers the footwear they desire in engaging shopping environments, including more than 1,240 retail stores and branded e-commerce websites. Its Journeys,

Genesco Inc. to Present at 2026 ICR Conference on January 12, 2026

Tue, 23 Dec 2025 06:50:00 -0500

About Genesco Inc.

Genesco Inc. to Present at 2026 ICR Conference on January 12, 2026

Tue, 23 Dec 2025 06:50:00 -0500

About Genesco Inc.

Genesco Inc. to Present at 2026 ICR Conference on January 12, 2026

Tue, 23 Dec 2025 06:50:00 -0500

About Genesco Inc.

Genesco Inc. to Present at 2026 ICR Conference on January 12, 2026

Tue, 23 Dec 2025 06:50:00 -0500

About Genesco Inc.

Genesco Inc. to Present at 2026 ICR Conference on January 12, 2026

Tue, 23 Dec 2025 06:50:00 -0500

About Genesco Inc.

Genesco Inc. to Present at 2026 ICR Conference on January 12, 2026

Tue, 23 Dec 2025 06:50:00 -0500

About Genesco Inc.

Genesco Inc. to Present at 2026 ICR Conference on January 12, 2026

Tue, 23 Dec 2025 06:50:00 -0500

About Genesco Inc.

Genesco Inc. to Present at 2026 ICR Conference on January 12, 2026

Tue, 23 Dec 2025 06:50:00 -0500

About Genesco Inc.

Genesco Inc. to Present at 2026 ICR Conference on January 12, 2026

Tue, 23 Dec 2025 06:50:00 -0500

About Genesco Inc.

Actinium presents breast cancer data for ATNM-400 at medical conference

Fri, 12 Dec 2025 08:45:43 -0500

Actinium Pharmaceuticals Inc. (NYSE American: ATNM) presented preclinical data for its experimental cancer treatment ATNM-400 at the 2025 San Antonio Breast Cancer Symposium. The data showed activity against multiple breast cancer types, including hormone receptor-positive, triple-negative, and treatment-resistant forms.

The company reported that ATNM-400 demonstrated tumor growth inhibition in laboratory models of hormone receptor-positive and triple-negative breast cancer. The treatment also showed activity in models resistant to standard therapies tamoxifen and trastuzumab, according to the press release.

ATNM-400 is designed to deliver Actinium-225 alpha-particle radiation to cancer cells. The treatment targets an antigen that the company states is overexpressed in breast cancer

Actinium presents breast cancer data for ATNM-400 at medical conference

Fri, 12 Dec 2025 08:45:43 -0500

ATNM-400 is designed to deliver Actinium-225 alpha-particle radiation to cancer cells. The treatment targets an antigen that the company states is overexpressed in breast cancer

Actinium presents breast cancer data for ATNM-400 at medical conference

Fri, 12 Dec 2025 08:45:43 -0500

ATNM-400 is designed to deliver Actinium-225 alpha-particle radiation to cancer cells. The treatment targets an antigen that the company states is overexpressed in breast cancer

Actinium presents breast cancer data for ATNM-400 at medical conference

Fri, 12 Dec 2025 08:45:43 -0500

ATNM-400 is designed to deliver Actinium-225 alpha-particle radiation to cancer cells. The treatment targets an antigen that the company states is overexpressed in breast cancer

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative,

Fri, 12 Dec 2025 08:45:00 -0500

- ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the HER2 therapy trastuzumab

- The Actinium-225 alpha-emitter payload of ATNM-400 induced irreversible double-strand DNA breaks and has the potential to produce potent localized tumor killing with reduced off-target lung toxicity that limits the use of antibody drug conjugates